Please check your internet connection and try again.
## Sodium Phosphate Enema
### Overview
Sodium phosphate enema is a hypertonic saline solution used as a stimulant laxative for bowel cleansing.
### Primary Indications
Bowel preparation for diagnostic procedures (e.g., colonoscopy, sigmoidoscopy) or surgical procedures. Relief of occasional constipation.
### Adult Dosing
* **Bowel Preparation:** Typically, one 4.5 oz (133 mL) enema is administered rectally, as directed by the prescribing information or physician. A second dose may be administered as directed.
* **Constipation:** One 4.5 oz (133 mL) enema administered rectally. Do not use more than one enema in a 24-hour period.
### Pediatric Dosing
* **Children 2 to under 12 years:** One 2.25 oz (66 mL) enema rectally, as directed.
* **Children under 2 years:** Use is generally not recommended due to increased risk of serious adverse events. Consult a pediatrician.
### Dose Adjustments
* **Renal Impairment:** Use with caution. Monitor electrolytes closely, especially in patients with pre-existing renal disease.
* **Heart Failure:** Use with caution due to potential for fluid and electrolyte shifts.
### Contraindications
* Congenital megacolon.
* Heart failure.
* Renal impairment.
* Abdominal obstruction or severe constipation.
* Congenital or acquired megacolon.
* Patients with impaired gag reflex.
* Young children (under 2 years).
* Known hypersensitivity to sodium phosphate.
### Adverse Effects
Common: Abdominal cramping, nausea, vomiting, bloating, anal irritation.
Serious:
* **Hyperphosphatemia:** Can lead to hypocalcemia, tetany, cardiac arrhythmias, and renal failure.
* **Hyponatremia:** Can lead to seizures, confusion, and cerebral edema.
* **Dehydration:** Especially in children and the elderly.
* **Hypersensitivity reactions.**
* **Rectal perforation:** Reported with excessive use or in patients with certain conditions.
### Key Drug Interactions
* **Diuretics:** Increased risk of electrolyte disturbances.
* **ACE inhibitors/ARBs:** Increased risk of hyperkalemia.
* **Calcium channel blockers:** Increased risk of hyperkalemia.
* **Drugs affecting kidney function:** Increased risk of renal toxicity.
### Monitoring
* Electrolytes (sodium, potassium, phosphate, calcium) before and after use, especially in at-risk populations.
* Renal function (creatinine).
* Signs of dehydration.
* Signs of electrolyte imbalance (e.g., muscle cramps, confusion, arrhythmias).
### Clinical Pearls
* Ensure adequate oral hydration before and after administration.
* Administer slowly and at room temperature.
* Avoid use in patients with compromised intestinal motility or at risk for fluid/electrolyte imbalance.
* This product can cause rapid and potentially severe fluid and electrolyte shifts. Careful patient selection and monitoring are crucial.
* A history of cardiac, renal, or hepatic disease significantly increases the risk of adverse events.
***
*Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider and refer to the most current prescribing information for any medication.*
